VivoSeq
Other

Ketamine

0

Pipeline Programs↗

16

Active Trials↗

8

Companies Involved↗

Ketamine is an early-stage landscape with 0 programs across 8 companies. The most active players are Supernus Pharmaceuticals, Inc., Johnson & Johnson, Javelin Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

72/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalJ

Javelin Pharmaceuticals

0 programs

PreclinicalJohnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalT

Taisho Pharmaceutical R&D Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

128

clinical trials

Completed68 · 53%
Unknown status17 · 13%
Terminated16 · 13%
Withdrawn11 · 9%
Recruiting8 · 6%
Not yet recruiting4 · 3%
Other4 · 3%

Clinical Trials

Trial Activity

128 trials

Imaging Neural Correlates of Ketamine Using PET/MR
Recruiting·MMedical University of Vienna·Phase 1·NCT04587778·65 enrolled
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Recruiting·YYale University·Phase 1·NCT05915013·50 enrolled
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Recruiting·YYale University·Phase 2·NCT05786066·30 enrolled
Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
Recruiting·SStanford University·Phase 2·NCT05940324·150 enrolled
RIVER At Home Ketamine Protocols
Recruiting·RRIVER Foundation·N/A·NCT06070766·50,000 enrolled
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
Recruiting·—·Phase 1·NCT06085937·50 enrolled
Understanding Ketamine's Dissociative Effects (KD Study)
Recruiting·SStanford University·Phase 1·NCT04861051·20 enrolled
Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI
Recruiting·—·Phase 2·NCT04600089·30 enrolled
Understanding How Ketamine Brings About Rapid Improvement in OCD
Active, not recruiting·SStanford University·Phase 2·NCT02624596·120 enrolled
Effects of Local Ketamine in Orthognathic Procedures
Active, not recruiting·—·N/A·NCT07066306·40 enrolled
Optimal Timing of Ketamine Initiation for SCD Pain
Not yet recruiting·—·Phase 3·NCT07450430·90 enrolled
Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome
Not yet recruiting·MMassachusetts General Hospital·Phase 1·NCT06698848·120 enrolled
Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts
Not yet recruiting·NNew York State Psychiatric Institute·Phase 4·NCT07139106·12 enrolled
Ketamine in Central Sensitization
Not yet recruiting·UUniversity Hospitals Cleveland Medical Center·Phase 4·NCT07182032·126 enrolled
Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)
Enrolling by invitation·MMedical University of Gdansk·N/A·NCT05565352·140 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)